Tonix Pharmaceuticals Secures Major Medicare Deal for TONMYA, Expanding Coverage to 46% of U.S. Lives — Tonix Pharmaceuticals Holding Corp.

Event summary

Tonix Pharmaceuticals secures a major managed Medicare payer agreement for TONMYA, adding approximately 9 million Medicare lives effective January 1, 2027.
With prior commercial and Medicaid coverage, TONMYA will cover approximately 46% of all U.S. covered lives by January 1, 2027.
Tonix plans to expand its sales force to 150 representatives by mid-third quarter 2026 to capitalize on growing market access.
TONMYA is the first new prescription medicine for fibromyalgia in over 15 years, with U.S. market exclusivity until 2034.

The big picture

Tonix Pharmaceuticals is rapidly expanding TONMYA's market reach, positioning itself as a key player in the fibromyalgia treatment space. The Medicare agreement, combined with prior commercial and Medicaid coverage, underscores the growing recognition of TONMYA’s value proposition. As Tonix scales its sales force, the company aims to capitalize on unmet medical needs in a chronic pain disorder affecting over 10 million U.S. adults.

What we're watching

Market Penetration: How Tonix will leverage the expanded Medicare coverage to accelerate TONMYA adoption among fibromyalgia patients.
Sales Force Effectiveness: Whether the 50% increase in sales representatives will translate into meaningful prescription growth and market share gains.
Competitive Dynamics: The pace at which Tonix can sustain its commercial momentum against existing fibromyalgia treatments amid patient dissatisfaction.